Novartis | NOVN - Себестоимость





Себестоимость Изменить Дата
AbbVie USD 4.22B 329M 2026-03
Alcon AG USD 1.18B 26M 2026-03
Almirall EUR 191.5M 2.29M 2025-12
Amgen USD 1.6B 187M 2026-03
AstraZeneca USD -204M 3.48B 2026-03
Autolus Therapeutics Ltd USD 24.57M 762K 2026-03
Bayer EUR 5.23B 731M 2026-03
Biogen USD 797.5M 302M 2026-03
Bristol-Myers Squibb USD 3.86B 1.07B 2026-03
Eli Lilly USD 3.58B 205M 2026-03
Fresenius EUR 4.45B 262M 2025-12
Fresenius Medical Care EUR 3.43B 248M 2026-03
Genmab DKK 81M 23M 2025-12
Gilead Sciences USD 1.44B 174M 2026-03
GlaxoSmithKline GBP 1.88B 736M 2026-03
GRIFOLS EUR 1.08B 214.82M 2026-03
Hikma Pharmaceutical USD 959M 492.5M 2025-12
J&J USD 8.07B 103M 2026-03
Lakefront Biotherapeutics EUR 4.8M 4.34M 2026-03
Lonza CHF 2.28B 189M 2025-06
Merck EUR 2.07B 219M 2026-03
Merck USD 2.94B 380M 2026-03
Novartis USD 3.46B 83M 2026-03
Novartis USD 3.46B 83M 2026-03
Novo Nordisk DKK 13.6B 1.55B 2026-03
Orion EUR 163.7M 22.9M 2026-03
Pfizer USD 4.59B 1.7B 2026-03
Philips EUR 2.14B 669M 2026-03
Recordati EUR 202.6M 13.03M 2026-03
Regeneron Pharmaceuticals USD 669.4M 84.8M 2026-03
Roche Holding CHF 8.48B 4.61B 2025-12
Sanofi EUR 3.67B 621M 2026-03
UCB EUR 1.07B 146M 2025-12